TraderByInstinct

20/50 SMA breach on volume here, see the DMI cross over

NASDAQ:CLVS   None
2
Rising RSI, 04/12 is the FDA discussion for Roceletinib therapy

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.